Benjamin Amendolara
Columbia University
11 Papers
62 Citations
Benjamin Amendolara is an academic researcher from Columbia University. The author has contributed to research in topics: Glioma & PTEN. The author has an hindex of 6, co-authored 8 publications. Previous affiliations of Benjamin Amendolara include NewYork–Presbyterian Hospital & Semel Institute for Neuroscience and Human Behavior.
Chat about Author
Papers
A secreted PTEN phosphatase that enters cells to alter signaling and survival.
Benjamin D. Hopkins,Barry Fine,Nicole Steinbach,Nicole Steinbach,Meaghan Dendy,Zachary Rapp,Jacquelyn Shaw,Jacquelyn Shaw,Kyrie Pappas,Kyrie Pappas,Jennifer S. Yu,Cindy Hodakoski,Sarah M. Mense,Joshua U. Klein,Joshua U. Klein,Sarah Pegno,Maria Luisa Sulis,Maria Luisa Sulis,Hannah E. Goldstein,Hannah E. Goldstein,Benjamin Amendolara,Benjamin Amendolara,Liang Lei,Liang Lei,Matthew Maurer,Matthew Maurer,Jeffrey N. Bruce,Peter Canoll,Peter Canoll,Hanina Hibshoosh,Hanina Hibshoosh,Ramon Parsons +31 more
TL;DR: A 576–amino acid translational variant of PTEN, termed PTEN-Long, that arises from an alternative translation start site 519 base pairs upstream of the ATG initiation sequence, adding 173 N-terminal amino acids to the normal PTEN open reading frame may have therapeutic uses.
The Transcriptional Regulatory Network of Proneural Glioma Determines the Genetic Alterations Selected during Tumor Progression
Adam M. Sonabend,Mukesh Bansal,Paolo Guarnieri,Liang Lei,Benjamin Amendolara,Craig R. Soderquist,Richard Leung,Jonathan Yun,Benjamin C. Kennedy,Julia Sisti,Samuel S. Bruce,Rachel A. Bruce,Reena Shakya,Thomas Ludwig,Steven S. Rosenfeld,Peter A. Sims,Jeffrey N. Bruce,Andrea Califano,Peter Canoll +18 more
TL;DR: Deletion of p53 at the time of tumor initiation obviated the acquisition of later deletions, establishing a link between the proneural transcriptional network and the subtype-specific deletions selected during glioma progression.
67
The transcriptional regulatory network of proneural glioma determines the genetic alterations selected during tumor progression.
Adam M. Sonabend,Mukesh Bansal,Paolo Guarnieri,L. Lei,Benjamin Amendolara,Craig Soderquist,Richard Leung,Jonathan Yun,Benjamin Kennedy,Julia Sisti,Samuel Bruce,Rachel Bruce,Reena Shakya,Thomas Ludwig,Steven Rosenfeld,Peter A Sims,Jeffrey N. Bruce,Andrea Califano,Peter Canoll +18 more
TL;DR: Deletion of p53 at the time of tumor initiation obviated the acquisition of later deletions, establishing a link between the proneural transcriptional network and the subtype-specific deletions selected during glioma progression.
15
Lab-experimental (pre-clinical) therapeutics and pharmacology
Fa H. Yang,Bo Zhang,Duo J. Zhou,Li Bie,Maxwell W. Tom,Daryl C. Drummond,Theodore Nicolaides,Sabine Mueller,Anuradha Banerjee,John W. Park,Michael D. Prados,David C. James,Nalin Gupta,Rintaro Hashizume,Garth W. Strohbehn,Jiangbing Zhou,Michael C. Fu,Toral R. Patel,Joseph M. Piepmeier,W. M. Saltzman,Qian Xie,Jennifer Johnson,Robert Bradley,Maria Libra Ascierto,Liang Kang,Julie Koeman,Francesco M. Marincola,Michael Briggs,Kirk Tanner,George F. Vande Woude,Shota Tanaka,Lindsay K. Klofas,Hiroaki Wakimoto,Darrell R. Borger,A. J. Iafrate,Tracy T. Batchelor,Andrew S. Chi,Achuthamangalam Madhankumar,Becky Slagle-Webb,Elias Rizk,Kimberly Harbaugh,James R. Connor,Gobinda Sarkar,Geoffry L. Curran,Robert B. Jenkins,Kazuhiko Kurozumi,Tomotsugu Ichikawa,Manabu Onishi,Kentaro Fujii,Joji Ishida,Yosuke Shimazu,Isao Date,Karen Ebsworth,Matthew J. Walters,Linda S. Ertl,Yu Wang,Robert D. Berahovich,Penglie Zhang,Jay P. Powers,Shie-Chau Liu,Reem Al Omran,Timothy J. Sullivan,Juan C. Jaen,Martin Brown,Thomas J. Schall,Nitta Yusuke,Saki Shimizu,Yukiko Shishido-Hara,Yoshiaki Shiokawa,Motoo Nagane,Jie Wang,Ke Sai,Fu-Rong Chen,Zhong-ping Chen,Zhendong Shi,Junxia Zhang,Kailiang Zhang,Lei Han,Luyue Chen,Xiaomin Qian,Anling Zhang,Guangxiu Wang,Zhifan Jia,Peiyu Pu,Chunsheng Kang,Ling-Yuan Kong,Tiffany Doucette,Sherise D. Ferguson,Jack Hachem,Yuhui Yang,Jun Wei,Waldemar Priebe,Gregory N. Fuller,Wei Qiao,Ganesh Rao,Amy B. Heimberger,Pin-Yuan Chen,Tomoko Ozawa,Daryl C. Drummond,Raquel Santos,Jacqueline De La Torre,Christina Ng,Edgar L. Lepe,Nicholas Butowski,Michael D. Prados,Krystof S. Bankiewicz,C. David James,Zhixiang Cheng,Yuanying Gong,Yufang Ma,Susanne Muller-Knapp,Stefan Knapp,Jialiang Wang,E. Antonio Chiocca,Balveen Kaur,John S. Yu,Valeria Judkowski,Alcinette Bunying,Jianfei Ji,Zhenhua Li,James Bender,Clemencia Pinilla,Vasisht Srinivasan,Marissa Dombovy-Johnson,Eleanor B. Carson-Walter,Kevin A. Walter,Zhiyuan Xu,Britney Popp,David Schlesinger,Lloyd S. Gray,Jason P. Sheehan,Stephen T. Keir,Henry S. Friedman,Darell D. Bigner,Carmen Kut,Betty Tyler,Elliot McVeigh,Xingde Li,Daniel Herzka,Stuart A. Grossman,Joseph L. Lasky,Yuntao Wang,Eduard H. Panosyan,W Hans Meisen,Jayson Hardcastle,Jeffrey Wojton,Eric S. Wohleb,Christopher Alvarez-Breckenridge,Michał Nowicki,Jonathan P. Godbout,Sang Y. Lee,Jonas M. Sheehan,Shaoman Yin,Stefan Kaluz,Saroja N. Devi,Rita de Noronha,K. C. Nicolaou,Erwin G. Van Meir,Jean E. Lachowicz,Michel Demeule,Christian Che,Sasmita Tripathy,Scott Jarvis,Jean-Christophe Currie,Anthony Regina,Tran N. Nguyen,Jean-Paul Castaigne,Katarzyna Zielinska-Chomej,Chitralekha Mohanty,Kristina Viktorsson,Rolf Lewensohn,James J. Driscoll,Samer Alsidawi,Ronald E. Warnick,Olivier Rixe,Ana C. deCarvalho,Susan M. Irtenkauf,Laura Hasselbach,Hong Xin,Tom Mikkelsen,Jonathan H. Sherman,Alan Siu,Olga Volotskova,Michael Keidar,Denise M. Gibo,Peter J Dickinson,John L. Robertson,John H. Rossmeisl,Waldemar Debinski,Smita Nair,Robert Schmittling,David Boczkowski,Gerald E. Archer,John Sampson,Duane A. Mitchell,Ian S. Miller,Sebastien Didier,David W. Murray,Magimairajan Issaivanan,Salvatore J. Coniglio,Jeffrey E. Segall,Yousef Al-Abed,Marc Symons,Abbas Fotovati,Kaiji Hu,Hiro Wakimoto,Joanna Triscott,Jeffrey A. Bacha,D.M. Brown,Sandra E. Dunn,David J. Daniels,Timothy E. Peterson,Allan B. Dietz,Gaylord J. Knutson,Ian F. Parney,Roberto J. Diaz,Brian Golbourn,Daniel Picard,Christian A. Smith,Annie Huang,James T. Rutka,Norihiko Saito,Jun Fu,Jun Yao,Shuzhen Wang,Dimpy Koul,W.K. A. Yung,Ying Yuan,Erik P. Sulman,Howard Colman,Frederick F. Lang,Emily A. Slat,Erik D. Herzog,Joshua B. Rubin,Arthur S. Carminucci,Benjamin Amendolara,Richard Leung,Liang Lei,Peter Canoll,Jeffrey N. Bruce,Jeffrey Wojton,Zhengtao Chu,Chang-Hyuk Kwon,Lionel M.L. Chow,Mary B. Palascak,Robert S. Franco,Tristan Bourdeau,Sherry Thornton,Xiaoyang Qi,Gaspar J. Kitange,Ann C. Mladek,Dan Su,Brett L. Carlson,Mark A. Schroeder,Jenny L. Pokorny,Katrina K. Bakken,Shiv K. Gupta,Paul A. Decker,Wenting Wu,Jann N. Sarkaria,Marc P. Oddou,Alexis Mollard,Lee T. Call,Hariprasad Vakayalapati,Steven L. Warner,Sunil Sharma,David J. Bearss,Thomas C. Chen,Heeyeon Cho,Weijun Wang,Florence M. Hofman,Catherine Flores,David Snyder,Luis Sanchez-Perez,Christina Pham,Henry S. Friedman,Eric C. Woolf,Mohammed G. Abdelwahab,Gregory H. Turner,Mark C. Preul,Andy G. Lynch,Jong M. Rho,Adrienne C. Scheck,Laurent Salphati,Timothy P. Heffron,Bruno Alicke,Kai Barck,Richard A. Carano,Jonathan Cheong,Joan Greve,Leslie B. Lee,Merry Nishimura,Jodie Pang,Emile G. Plise,Hani Bou Reslan,Xiaolin Zhang,Stephen G. GOuld,Alan G. Olivero,Heidi S. Phillips,Gelareh Zadeh,Shahrzad Jalali,David J. Voce,Zhang Wei,Kang Shijun,Khodarev Nikolai,Wahlstrom Josh,Crawley Clayton,Yamini Bakhtiar,Ryan Alkins,Alison Burgess,Milan Ganguly,Winfried S. Wels,Kullervo Hynynen,Yan M. Li,Huang Jun,Vallera Daniel,Hall A. Walter,Hiroshi Nakashima,Tran T. Nguyen,Imran Shalkh,William F. Goins,Ennio Antonio Chiocca,Ilya V. Pyko,Mitsutoshi Nakada,Natsuki Furuyama,Teng Lei,Yutaka Hayashi,Kazuyuki Kawakami,Toshinari Minamoto,Aliaksandr S. Fedulau,Jun-ichiro Hamada +330 more
TL;DR: Rg3-NPs may be a potent cell-cycle regulation drug targeting the M-phase in glioblastoma cell lines and induced the expression of the apoptotic and antimigratory protein p53 in cell lines.
The Effect of Fasudil on Glioma Cell Migration
Athanassios Dovas,Benjamin Amendolara,Christine Wang,Peter Canoll +3 more
- 17 Jan 2017
TL;DR: The results indicated that fasudil is a potent inhibitor of migration and also accordingly decreases regulatory light chain phosphorylation in glioma cells, suggesting that fAsudil could be a good potentia l candidate for future in vivo studies and contribute to current therapeutic options for the treatment of gliomas.